2023/08/02 ALA-3000 has received an Intention to Grant (IGRA) from European Patent Office (EPO) after examination. (Patent Application No. 20739053.5) Post author:alarpharm Post published:10 . 8 . 2023 Post category:Media releases You Might Also Like 2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020 2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021 2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021 2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
2020/07/22 ALA -1000 Receive notice of patent allowance from the Mexican Institute of Industrial Property (IMPI) 13 . 8 . 2020
2021/11/30 ALA-1000 Received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia, Application No. P00201902139.. 17 . 12 . 2021
2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder 28 . 10 . 2021
2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021
2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. 3 . 5 . 2021
